Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
(firmenpresse) - July 5, 2021 6:00 AM EDT
LONDON, ONTARIO - July 5, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, held its annual shareholder meeting (the Meeting) via the virtual meeting platform of TSX Trust Company for the following purposes:
1. to elect the Corporations board of directors (the Board);
2. to appoint the Corporations auditor; and
3. to pass ordinary resolutions to amend and restate the Corporations Option Plan & Deferred Share Unit Plan (the Incentive Plan) for the following purposes: (a) to increase the fixed number maximum of shares reserved for grant of options and (b) to increase the fixed number maximum of Deferred Share Units available for award pursuant to the Deferred Share Unit Plan component of the Incentive Plan.
Results of the Meeting:
- Frank A. Holler, Dr. Mohammad Azab, Jeffrey A. Bacha, Deborah M. Brown, James T. Parsons and Dr. Philip M. Toleikis were elected as members of the Board for the following year;
- Davidson & Company, Chartered Professional Accountants, was appointed auditor of the Corporation for another year; and
- disinterested shareholders approved the increase in the fixed number maximum of common shares reserved for the grant of options and the increase of the fixed number maximum of deferred share units available for award pursuant to the Incentive Plan.
I would like to thank our shareholders for their Meeting participation and continuing support. From a financial point of view combined with our latest encouraging interim diabetes clinical results (having established insulin independence in our most advanced study patient for over 14 months) and the stage of our advancing pharmaceutical collaborations, Sernova is in the strongest position in its history, said Dr. Philip Toleikis, President & CEO of Sernova Corp.
Toleikis continued, Improving the quality of life for our patients through expansion of our clinical programs and further increasing shareholder value are top priorities as we work to achieve important milestones over the next 6-12 months.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
investorrelations(at)sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute forward-looking statements that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect managements beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernovas actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the companys quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Recce Pharmaceuticals Ltd.: Bonus Canadian Scientific Research & Experimental Development Rebate Received">
" alt="Terra Capital Increases Its Position in Empress Royalty">
Datum: 05.07.2021 - 06:08 Uhr
Sprache: Deutsch
News-ID 1568782
Anzahl Zeichen: 3343
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 480 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sernova Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
